These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36211189)

  • 1. Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients.
    Samadhiya S; Sardana V; Bhushan B; Maheshwari D; Goyal R; Pankaj
    Ann Indian Acad Neurol; 2022; 25(4):692-697. PubMed ID: 36211189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial.
    Eishi-Oskouei A; Basiri K
    Curr J Neurol; 2021 Jan; 20(1):1-7. PubMed ID: 38011420
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
    Han HJ; Shin HY; Choi YC; Kim SM; Kim SW
    Redox Rep; 2022 Dec; 27(1):79-84. PubMed ID: 35296219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
    Sawada H
    Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.
    Okada M; Yamashita S; Ueyama H; Ishizaki M; Maeda Y; Ando Y
    eNeurologicalSci; 2018 Jun; 11():11-14. PubMed ID: 29928711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated pulmonary recovery in a veteran with late stage bulbar ALS following edaravone treatment and cessation.
    Verma S; Lim J; Buscemi-Kimmins T; Brose SW
    J Spinal Cord Med; 2022 Jul; 45(4):638-642. PubMed ID: 34982644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.
    Saccà F; Quarantelli M; Rinaldi C; Tucci T; Piro R; Perrotta G; Carotenuto B; Marsili A; Palma V; De Michele G; Brunetti A; Brescia Morra V; Filla A; Salvatore M
    J Neurol; 2012 Jan; 259(1):132-8. PubMed ID: 21706151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
    Li X; Koeberl DD; Lutz MW; Bedlack R
    J Clin Neuromuscul Dis; 2023 Jun; 24(4):214-221. PubMed ID: 37219865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug.
    Ortiz JF; Khan SA; Salem A; Lin Z; Iqbal Z; Jahan N
    Cureus; 2020 Oct; 12(10):e10818. PubMed ID: 33173626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.